Chart-Typ:
Zeitraum:
| 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More | BEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies... ► Artikel lesen |
| bioAffinity Technologies, Inc. Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 | SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced... ► Artikel lesen |
| WallachBeth Capital LLC: WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering | JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced... ► Artikel lesen |
| Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) | - LUMUS trial did not meet its primary and secondary endpoints in the overall trial population - - Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high)... ► Artikel lesen |
| Alumis Inc.: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements | - ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO - - Alumis remains on track to submit its New Drug Application... ► Artikel lesen |
| Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen |
| Biotech Stocks At 52-Week Highs - MiniMed Group +10%, Pulse Biosciences, Solventum, Royalty Pharma, Apogee Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 1, 2026, as various companies reported financial results and reached certain regulatory milestones.MiniMed... ► Artikel lesen |
| Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen |
| Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.